Research ArticleCancer

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

See allHide authors and affiliations

Science Translational Medicine  07 Sep 2011:
Vol. 3, Issue 99, pp. 99ra86
DOI: 10.1126/scitranslmed.3002442

Log in to view full text


Navigate This Article